louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06661941: Predictive Tools for the Presence of Significant Coronary Artery Disease Requiring Intervention in Chronic Hemodialysis Patients
Official title: Predictive Tools for the Presence of Significant Coronary Artery Disease Requiring Intervention in Chronic Hemodialysis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemodialysis
Coronary Arterial Disease (CAD)
ESRD (End Stage Renal Disease)
Keywords: hemodialysis
coronary artery disease
electrocardiography
echocardiography
troponin
coronary angiography
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2024-10-28
Enrollment: 149
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult HD patients undergoing CAG at King Chulalongkorn Memorial Hospital of all indications between January 2017 and March 2021 with complete data

Brief summary: Medical record data of all HD patients undergoing coronary angiography (CAG) at King Chulalongkorn Memorial Hospital between January 2017 and March 2021 were retrospectively reviewed as a discovery cohort to identify factors discriminating patients with and without significant CAG-established CAD. HD patients receiving CAG between April 2021 and March 2023 were assigned as a validation cohort.

Detailed description: Background: Hemodialysis (HD) patients have increased cardiovascular risk. Coronary artery disease (CAD) may not typically manifest in these patients and the investigational results can be confounded by the fluctuation of body fluid and electrolytes. This study explored the accuracy of these findings in identifying CAD in HD patients.

Methods: Medical record data of all HD patients undergoing coronary angiography (CAG) at King Chulalongkorn Memorial Hospital between January 2017 and March 2021 were retrospectively reviewed as a discovery cohort to identify factors discriminating patients with and without significant CAG-established CAD. HD patients receiving CAG between April 2021 and March 2023 were assigned as a validation cohort.

Eligibility criteria: Inclusion Criteria:

* All adult HD patients undergoing CAG at King Chulalongkorn Memorial Hospital of all indications between January 2017 and March 2021 with complete data

Exclusion Criteria:

* Those resinged for using their clinical data for the research

Primary outcomes:
measure: Presence of coronary artery disease
timeFrame: Any positive result between January 2017 and March 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Faculty of Medicine, Chulalongkorn University
Study officials:
References:
citation: Go AS, Bansal N, Chandra M, Lathon PV, Fortmann SP, Iribarren C, Hsu CY, Hlatky MA; ADVANCE Study Investigators. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. J Am Coll Cardiol. 2011 Oct 4;58(15):1600-7. doi: 10.1016/j.jacc.2011.07.010.
Clinical trial NCT00570141: OASIS Wound Matrix (Oasis) Mechanism of Action
Official title: Case Study Documentation of Subjects With Either Diabetic Foot Ulcers or Venous Stasis Ulcers Being Treated With OASIS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetic Foot Ulcers (DFU)
Venous Stasis Ulcers (VSU)
Lead sponsor: Healthpoint
Sponsor class: INDUSTRY
First posted: 2007-12-10
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: OASIS Wound Matrix (Oasis) will be applied to wounds, with sequential biopsy of healing wounds to explore the mechanism of action.

Detailed description: Wound types will be Diabetic Foot Ulcers (DFU) and Venous Stasis Ulcers (VSU).

Eligibility criteria: Inclusion Criteria:

* Diabetic foot ulcer (DFU) or venous stasis ulcer (VSU) of the leg, with certain restrictions on size, duration and underlying health

Exclusion Criteria:

* Contraindications or hypersensitivity to the use of the study medications or their components

Primary outcomes:
measure: Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First.
timeFrame: Baseline and weekly up to 12 weeks
measure: Percent Wounds Closed
timeFrame: baseline and 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Smith
country: United States
facility: Sparks Regional Medical Center
state: Arkansas
city: St. Louis
country: United States
facility: Bay Pines VA Healthcare System
state: Missouri
city: St. George
country: United States
facility: Dixie Regional Medical Center Wound Clinic
state: Utah
Study officials:
affiliation: Bay Pines VA Healthcare System
name: W. Payne, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Dixie Regional Medical Center Wound Clinic
name: Carl Van Gils, DPM, CWS
role: PRINCIPAL_INVESTIGATOR
affiliation: Sparks Regional Medical Center
name: Davin Haraway, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03475641: Femoral Nerve Blockade in Endovenous Laser
Official title: Femoral Nerve Blockade in Endovenous Laser During Varicose Vein Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: pain
femoral nerve blockade
varicose vein
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2018-03-23
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Varicose veins affect a majority of adult population in the western world. They decrease quality of life and may also cause venous ulcers. Therefore varicose vein treatments are justified. Currently endovenous thermal ablation is a treatment of choice for varicose veins. At the outpatient setting, however, treating both limbs at the same time may be painful to the patient especially, if simultaneous phlebectomies are performed.

The study aims to evaluate, if femoral nerve blockade can significantly decrease pain during the procedure without prolonging the stay in the hospital.

Detailed description: Varicose veins affect a majority of adult population in the western world. They decrease quality of life and may also cause venous ulcers. Therefore varicose vein treatments are justified.

Thanks to technical advancement open surgery has been replaced By endovenous means. Currently endovenous thermal ablation is a golden standard for main trunk disease. For efficient patient and procedure flow majority of thermal ablations are performed at the outpatient setting. However, if patient is suffering from significant varicose veins, treating both legs, may be unpleasant to the patient.

Aim of the study is, whether addition of femoral nerve blockade to the tumescent anesthesia can decrease pain during the procedure without prolonging the stay in the hospital.

Eligibility criteria: Inclusion Criteria:

* Great saphenous vein insufficiency
* CEAP class 2-4

Exclusion Criteria:

* Neurological diseases
* Pregnancy
* CEAP 5-6
* BMI\>40
* Allergy to lidocain

Primary outcomes:
measure: Pain
timeFrame: Peri-procedural
Secondary outcomes:
measure: Pain
timeFrame: Pre-procedural
measure: Pain
timeFrame: 1h after the procedure
measure: Motoric paresthesias of the femoral nerve
timeFrame: After the phlebectomies
measure: Motoric paresthesias
timeFrame: through study completion, an average of 1 month
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Hospital, Finland
state: Uusimaa
Study officials:
affiliation: Head of Depratment
name: Anders Alback, MD,PhD
role: STUDY_CHAIR
affiliation: Head of Venous Department
name: Karoliina H Halmesmaki, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03883841: Fetal Vascular Hemodynamic Changes in Iron Deficiency Anemia
Official title: Fetal Vascular Hemodynamic Changes Before and After Treatment of Maternal Iron Deficiency Anemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Iron Deficiency Anemia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-03-21
Enrollment: 60
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study includes pregnant women 28 - 32 week gestation (calculated by the last menstrual period or by earlier ultrasound examination)

Brief summary: Iron deficiency anemia is a worldwide medical disorder. So far, it is the most common medical complication in pregnancy specially in developing countries. It is the cause of many adverse effects on mother and fetus and contributes significantly to high maternal mortality. Maternal iron deficiency anemia is frequently associated with premature delivery, low birth weight babies


Eligibility criteria: Inclusion Criteria:

* Pregnant women with gestational age 28-32 weeks
* singleton pregnancy
* iron deficiency anemia.

Exclusion Criteria:

* Multiple pregnancy
* antepartum hemorrhage
* major congenital fetal anomalies
* any other type of anemia other than iron deficiency anemia
* any acute or chronic maternal disease other than iron deficiency anemia.

Primary outcomes:
measure: The mean changes in middle cerebral artery Doppler of the fetus
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06773741: Emotional Care Competency Scale for Dementia: Development and Correlations With Knowledge, Attitudes, and Confidence
Official title: Development of an Emotional Care Competency Scale for Dementia Among Long-Term Care Professionals and Its Relationship to Knowledge, Attitudes, and Confidence in Dementia Care
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Dementia Patients Care
Emotional
Lead sponsor: Chang Gung University of Science and Technology
Sponsor class: OTHER
First posted: 2025-01-14
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Professionals working in dementia care within long-term care facilities, such as nurses, nursing assistants, or dementia case managers.

Brief summary: This study aims to develop an "Emotional Care Competency Scale for Dementia" targeting long-term care professionals and to explore the relationship between caregivers' emotional care competency and their knowledge, attitudes, and confidence in dementia care.

A mixed-methods approach will be employed in two exploratory phases:

Phase One: Scale Development Participants: Purposeful sampling will recruit experienced long-term care professionals.

Method: Conduct qualitative interviews; analyze the collected data using content analysis to code and categorize information; draft the initial version of the Emotional Care Competency Scale for Dementia based on the results.

Phase Two: Scale Validation and Relationship Analysis Objective: Validate the reliability and validity of the scale and examine the relationship between professionals' emotional care competency and their knowledge, attitudes, and confidence in dementia care.

Design: Longitudinal descriptive correlational study. Participants: Convenience sampling to recruit participants for two rounds of questionnaire surveys.

This study seeks to provide a comprehensive tool for assessing emotional care competencies among dementia care professionals and to understand how these competencies relate to their knowledge, attitudes, and confidence in delivering care.


Eligibility criteria: Inclusion Criteria:

- Aged 18 years or older. Currently working in a setting that provides dementia care. Currently engaged in nursing or caregiving services in the long-term care sector.

Able to communicate in Mandarin or Taiwanese. No history of mental illness.

Exclusion Criteria:

- Under 18 years of age. Suffering from significant physical or psychological illnesses.

Primary outcomes:
measure: Reliability and Validity Testing of the Dementia Emotional Care Competency Scale
timeFrame: Baseline and 6monthes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01068041: Effects of PH3 in Diabetic Nephropathy
Official title: Effects of PH3 in Diabetic Nephropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetic Nephropathy
Lead sponsor: PhytoHealth Corporation
Sponsor class: INDUSTRY
First posted: 2010-02-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy.

The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.


Eligibility criteria: Inclusion Criteria:

1. Males and Females between 18 and 70 years of age with type 1 or type 2 diabetes
2. Sitting blood pressure of \<=140/90 mm Hg
3. Serum creatinine \<=2.0 mg/dL
4. Urinary albumin: creatinine ratio between 30 mg/g to 1000 mg/g creatinine (of the first urine sample of the day)
5. Hemoglobin A1c \<=8%
6. Women of child-bearing potential must test negative in a pregnancy test and take contraception measures to prevent pregnancy and can not be breast-feeding
7. Voluntary written consent to participate in this study

Exclusion Criteria:

1. History of major cardiovascular or cerebrovascular events within 6 months prior to screening
2. History of cancer
3. Receiving chronic nonsteroidal anti-inflammatory therapy
4. History of diabetic ketoacidosis
5. Has clinically significant deviation from normal physical examination findings that, in the principal investigator's judgment, may interfere with the study evaluation or affect subject safety
6. Has participated in other investigational trials within 28 days prior to study enrollment
7. Has taken herbal medical treatment as prescription medication and/or over-the- counter medication, within 28 days prior to study enrollment.
8. Has known allergy to the study drug

Primary outcomes:
measure: Urinary Albumin/Creatinine Ratio (UACR)
timeFrame: 24 weeks
Secondary outcomes:
measure: Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Taipei
country: Taiwan
facility: Tri-Service General Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
Study officials:
affiliation: Taipei Veterans General Hospital, Taiwan
name: Wu Chang Yang, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tri-Service General Hospital
name: Yi-Jen Hung, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Taichung Veterans General Hospital
name: Huey-Herng Sheu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00711841: Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome
Official title: Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: HELLP Syndrome
Keywords: HELLP syndrome
dexamethasone
postpartum period
class I HELLP syndrome
Lead sponsor: Instituto Materno Infantil Prof. Fernando Figueira
Sponsor class: OTHER
First posted: 2008-07-09
Enrollment: 400
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 49
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of blood products and shorter hospital stay.

Detailed description: Patients with Class I HELLP Syndrome will be recruited for use os dexamethasone or placebo in the puerperium. Effects such as clinical course (blood pressure and diureses), laboratorial behaviour and complications will be compared. Duration of hospitalization will also be accessed.

Eligibility criteria: Inclusion Criteria:

* Postpartum women with Class I HELLP syndrome

Exclusion Criteria:

* Chronic users of corticosteroids
* Patients with chronic conditions affecting the laboratory parameters involved in the HELLP syndrome
* Women who had received antenatal corticosteroids to treat HELLP syndrome were excluded

Primary outcomes:
measure: severe maternal morbidity
timeFrame: postpartum
Secondary outcomes:
measure: hospital stay duration
timeFrame: postpartum
Other outcomes:
Locations:
city: Recife
country: Brazil
facility: Instituto Materno Infantil Prof. Fernando Figueira
state: Pernambuco
Study officials:
affiliation: IMIP
name: Leila Katz, pHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Katz L, Amorim M, Souza JP, Haddad SM, Cecatti JG; COHELLP Study Group. COHELLP: collaborative randomized controlled trial on corticosteroids in HELLP syndrome. Reprod Health. 2013 May 22;10:28. doi: 10.1186/1742-4755-10-28.
Clinical trial NCT04255641: Time - Lapse Analysis of Frozen Embryos
Official title: Is Morphokinetic Scoring by Time - Lapse Analysis of Embryos Undergoing Cryopreservation During IVF Associated With Post- Thaw Survival and Treatment Outcome: A Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Frozen Embryos
Lead sponsor: Carmel Medical Center
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 400
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All women who underwent embryo freezing and thawing between the years 2014-2019 in Carmel medical center

Brief summary: A retrospective analysis of embryo defrost cycles that were rated in the EmbryoScope system and frozen will be performed. The study will examine the possible association between the morphokinetic grading received by these embryos as fresh embryos before freezing, and their survival, the morphological grading they received after thawing, their proper rooting and live birth after thawing.


Eligibility criteria: Inclusion Criteria:

* All women who underwent embryo freezing and thawing between the years 2014-2019 in Carmel medical center

Exclusion Criteria:

* Lack of proper data

Primary outcomes:
measure: live birth
timeFrame: 1 day
measure: embryos survival after thawing
timeFrame: 1-2 days
measure: implantation in the uterus
timeFrame: 1 week
measure: post thaw grading
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Carmel Medical Center
Study officials:
References:
Clinical trial NCT02726841: Hybrid Treatment of Type B Aortic Dissection
Official title: Superiority Trial of Type b Aortic Dissection Treatment Combined With Implantation of Bare Metal Stent in Abdominal Part of Aorta Versus Conventional Type b Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Aortic Dissection Type B
Keywords: Thoracic aorta
Abdominal aorta
Stents
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
Sponsor class: NETWORK
First posted: 2016-04-04
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Authors hypothesize that thoracoabdominal aortic repair combined with bare metal stent implantation is superior over standard thoracoabdominal aortic repair.

Detailed description: Main hypothesis of this study is that thoracoabdominal aortic repair combined with bare metal stent implantation is better permanent neurological deficits, perioperative bleeding, malperfusion of viscera over conventional thoracoabdominal aortic repair.

Eligibility criteria: Inclusion Criteria:

* Patients with chronic aortic dissection type B
* Aortic size in descending thoracoabdominal aorta (TAA) \> 55 mm

Exclusion Criteria:

* concomitant cardiac pathology
* concomitant oncology diseases in the last 5 years
* acute aortic dissection
* aortic size in visceral zone \>45 mm
* connectivity tissue diseases

Primary outcomes:
measure: Permanent neurological events
timeFrame: 30 days
Secondary outcomes:
measure: Perioperative bleeding
timeFrame: 5 days after procedure
measure: Mortality
timeFrame: 6 months
measure: Visceral malperfusion
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology Ministry of Health care of Russian Federation
name: Alexander M. Chernyavskiy, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03601741: Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination
Official title: Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: MRSA
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 1
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: This is a prospective pilot study using a randomized, controlled, single blinded, crossover trial design, evaluating the effect of daily antimicrobial stethoscope diaphragm covers versus uncovered stethoscope. Stethoscopes will be cleaned Sani-cloth germicidal disposable wipes which are effective against MRSA. Each participant will then be randomly assigned to 7 days in either the intervention or the control arm. At the end of the 7 days participants stethoscopes will be cleaned again. This will be followed by another 7 days in the arm that they are not in during the first 7 days.

The primary endpoint is MRSA colony count from stethoscope diaphragms cultures at 7 days, focusing on the difference between the intervention and the control periods. The secondary endpoint is the rate of hospital acquired MRSA infection in patients treated by residents during each period.


Eligibility criteria: Inclusion Criteria:

* Internal Medicine Residents

Exclusion Criteria:

* NA

Primary outcomes:
measure: MRSA colony count cultured from stethoscope diaphragms
timeFrame: 7 Days
Secondary outcomes:
measure: Rate of hospital acquired MRSA infection in patients treated by participating residents
timeFrame: 14 Days
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Marwa Moussa, MD
role: PRINCIPAL_INVESTIGATOR
References: